27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US biotech major Amgen rolled out senior executives and a swish presentation in providing an update on two of its drugs in Phase III trials this week. 26 September 2024
The US Food and Drug Administration has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD). 5 February 2022
UK and USA-based biotech firm Orchard Therapeutics’ shares closed up 7.6% and rose a further 4.4% to $1.18 in after-hours trading on Friday, after the company gained clearance for Nation Health Service use in England and Wales for its stem cell therapy Libmeldy (atidarsagene autotemcel). 5 February 2022
Biotech major Amgen and privately-held Plexium have announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify new targeted protein degradation therapeutics toward historically challenging drug targets. 4 February 2022
GlaxoSmithKline’s Christine Roth is to leave the company to become the new head of the Oncology Strategic Business Unit at Bayer’s (BAYN: DE) Pharmaceuticals division. 4 February 2022
German pharma major Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. 4 February 2022
Propelled by a positive performance from immuno-oncology powerhouse Opdivo (nivolumab) and blood thinner Eliquis (apixaban), Bristol Myers Squibb reported revenues of $12 billion for the fourth quarter. 4 February 2022
The National Institute for Health and Care Excellence (NICE) has recommended that Jardiance (empagliflozin), from German family-owned pharma major Boehringer Ingelheim and marketed in partnership with Eli Lilly, will be recommended as a clinical and cost-effective treatment option for adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) as an add-on to optimized standard care. 4 February 2022
According to a filing with the Securities and Exchange Commission, US healthcare giant Johnson & Johnson has determined that it will record an intangible asset impairment charge related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of atopic dermatitis (AD) and Hidradenitis suppurativa (HS). 4 February 2022
A study led by researchers at the University of Texas MD Anderson Cancer Center reported in The Lancet that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma. 4 February 2022
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for patients with previously untreated advanced renal cell carcinoma (RCC) that is intermediate- or poor-risk, US pharma major Bristol Myers Squibb has revealed. 4 February 2022
Pharma trade group Medicines Australia is calling for the new National Medicines Policy (NMP) to be pushed back until after the federal election, expected in May. 4 February 2022
Beating analysts’ expectations, Eli Lilly put in a strong performance in the final quarter of 2021, propelled by its COVID-19 antibody therapy as well as diabetes med Trulicity (dulaglutide). 3 February 2022
French pharma major Sanofi has given itself a new look with a logo (pictured above) and unified brand that the company believes matches the transformed strategy that it has been pursuing since 2019. 3 February 2022
US biopharma firm Mersana Therapeutics’ shot up 9% to $4.67 in early trading, after it announced a research collaboration and license agreement with Janssen Biotech, a part of healthcare giant Johnson & Johnson, to discover novel antibody drug conjugates (ADCs) for three targets. 3 February 2022
UK-based Alliance Pharma (AIM: APH) saw its shares close down 6.9% at 105.54 pence today, after it provided an update on the Competition and Markets Authority (CMA) investigation first announced in May 2019 in which four companies, including Alliance, have been subject to a lengthy investigation. 3 February 2022
US biotech major Biogen today reported fourth quarter and full year 2021 financial results and provided an earnings forecast that was below expectations, sending the firm’s shares down 4.3% to $215.28 in pre-market trading. 3 February 2022